Tandem Therapeutics AG
TANDEM Tx is pioneering a mechano-targeted therapeutic platform designed to selectively target the extracellular matrix in fibrotic diseases. TANDEM’s peptide drug conjugates target mechanical changes in fibrotic niche, to home-in with precision while minimising off-target effects. This breakthrough approach can potentially transform fibrosis treatment across multiple organs. Our lead program is focused on progressive pulmonary fibrosis, a fatal disease with no cure.
Date, time and room information
May 5, 15:15 - 15:30, room Singapore
Category
Emerging biotech company
Title of the presentation
Targeting Fibrosis with Mechano-Sensitive Peptide Drug Conjugates
Speaker information
| Name | Position | Institution |
|---|---|---|
| Mamta Chabria | CEO |
